SSY Group (SEHK:2005) - Aandelenkoers, Nieuws & Analyse

2005 Overzicht aandelen

2005 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	2/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	3/6

Beloningen

Verhandeld tegen 61.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 5.81% per jaar groeien

De winst groeide het afgelopen jaar met 14.6%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Dividend van 4.72% wordt niet goed gedekt door vrije kasstromen

SSY Group Limited Concurrenten

Luye Pharma Group

SEHK:2186

HK$9.9b

Shandong Xinhua Pharmaceutical

SEHK:719

HK$9.9b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$11.5b

Grand Pharmaceutical Group

SEHK:512

HK$16.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SSY Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$3.81
52 Week Hoogtepunt	HK$5.20
52 Week Laag	HK$3.31
Bèta	0.62
11 maand verandering	-0.52%
3 maanden verandering	8.55%
1 Jaar Verandering	-23.34%
33 jaar verandering	1.06%
5 jaar verandering	-40.00%
Verandering sinds IPO	893.91%

Recent nieuws en updates

Recent updates

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Mar 28

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

Mar 06

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Feb 13

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

Dec 29

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

Sep 26

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

Sep 03

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

Aug 31

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

Jun 24

Rendement voor aandeelhouders

	2005	HK Pharmaceuticals	HK Markt
7D	-1.3%	0.8%	0.4%
1Y	-23.3%	-7.5%	12.0%

Rendement versus industrie: 2005 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -7.5 % opleverde.

Rendement versus markt: 2005 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 12 % opleverde.

Prijsvolatiliteit

Is 2005's price volatile compared to industry and market?
2005 volatility
2005 Average Weekly Movement	5.3%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 2005 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 2005 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	5,800	Jiguang Qu	www.ssygroup.com.hk

SSY Group Limited, een investeringsholding, onderzoekt, ontwikkelt, produceert, verhandelt en verkoopt verschillende farmaceutische producten aan ziekenhuizen en distributeurs in de Volksrepubliek China en daarbuiten. Het bedrijf biedt intraveneuze infusieoplossingen, waaronder niet-PVC-soft bags, rechtopstaande soft bags, PP-plastic flessen en infusieoplossingen in glazen flessen, evenals ampulinjecties. Het bedrijf levert ook injecties in kleine volumes, orale bereidingen, Chinese medicijnpreparaten en biologische bereidingen, evenals farmaceutische bulkproducten en medische materialen.

SSY Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van SSY Group zich tot de beurswaarde?
2005 fundamentele statistieken
Marktkapitalisatie	HK$11.57b
Inkomsten(TTM)	HK$1.37b
Inkomsten(TTM)	HK$6.47b

8.3x

Koers/Winstverhouding

1.7x

P/S-verhouding

Is 2005 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2005 resultatenrekening (TTM)
Inkomsten	HK$6.47b
Kosten van inkomsten	HK$2.95b
Brutowinst	HK$3.52b
Overige uitgaven	HK$2.15b
Inkomsten	HK$1.37b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.46
Brutomarge	54.39%
Nettowinstmarge	21.11%
Schuld/Eigen Vermogen Verhouding	47.7%

Hoe presteerde 2005 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.7%

Huidig dividendrendement

39%

Uitbetalingsratio

2005 Overzicht aandelen

Beloningen

Risicoanalyse

SSY Group Limited Concurrenten

SEHK:2186

HK$9.9b

SEHK:719

HK$9.9b

SEHK:570

HK$11.5b

SEHK:512

HK$16.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Recent updates

Chairman & CEO recently bought HK$3.4m worth of stock

Price target increased by 14% to HK$6.38

SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg)

SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China

SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China

Investor sentiment improves as stock rises 18%

Chairman & CEO recently bought HK$4.8m worth of stock

Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers

SSY Group Limited Announces Update on Product Development

Chairman & CEO recently bought HK$1.5m worth of stock

Consensus EPS estimates fall by 10%

Price target decreased by 10% to HK$5.58

SSY Group Limited Announces Update on Product Development

First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023)

SSY Group's (HKG:2005) Dividend Will Be HK$0.08

First half dividend increased to HK$0.08

SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024

SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited's (HKG:2005) P/E Is On The Mark

Investor sentiment deteriorates as stock falls 16%

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock